LONDON, June 30, 2026, 10:01 BST
- Renalytix Plc (LON:RENX) jumped 31.6% to 2.50p as of 9:41 a.m. London time. Trading volume hit 2.53 million shares, which is around 8.6 times its recent average.
- Diagnostics firm on AIM posted two-year real-world results from 2,470 patients at Mount Sinai and Wake Forest/Atrium Health.
- Renalytix closed at about 16% of its 52-week high, market cap holding near £11 million.
- London was in its normal trading hours at dateline. LSE runs from 0800 to 1630 local time.
Renalytix Plc (LON:RENX) surged at the open in London on Tuesday after the company released two-year real-world data on kidneyintelX.dkd. Still, turnover told a different story: while volume spiked, the cash value traded stayed low by institutional standards.
Shares jumped 31.58% to 2.50 pence at 9:41 a.m. BST, after closing at 1.90p. Google Finance put volume at 2.53 million shares, way above the 295,790 average—about 8.6 times normal. At 2.50p, that’s about £63,000 traded, roughly 0.6% of the 437.02 million shares out.
| Market yardstick | Tuesday reading |
|---|---|
| Renalytix last price | 2.50p |
| Move today | +31.58% |
| Turnover | 2.53 mln shares |
| 30-day average | 295,790 shares |
| Volume vs average | 8.6x |
| Market cap | £10.92 mln |
| Year range | 1.60p-15.50p |
| FTSE AIM All-Share index | 771.44, +0.17% |
Renalytix saw a big jump in volume on AIM, but that did little for investors watching the FTSE AIM All-Share add 0.17% to 771.44, according to delayed numbers from AJ Bell. Even after the move, Renalytix shares stayed down roughly 84% from their 52-week high of 15.50p.
Renalytix reported that its study tracked 2,470 patients with type 2 diabetes and early-stage chronic kidney disease at two U.S. health systems. The company said 29% of patients who were retested shifted to a lower risk group. SGLT2 inhibitor treatment reached 56% among high-risk patients. Patients who started out at high risk were 10.4 times more likely to have major kidney decline or kidney failure than those at low risk.
| Latest clinical data | Reported figure |
|---|---|
| Total patients in trial | 2,470 |
| Share of retested patients shifting to lower risk | 29% |
| High-risk patients on SGLT2 inhibitor | 56% |
| High-risk group using both SGLT2i and GLP-1 RA | 12% to 32% |
| Improvement in eGFR decline rate at two years | 43% |
| Drop in UACR | 23% |
| Reduction in HbA1c | 7.6% |
| Event odds high-risk vs low-risk | 10.4x |
Dr David Lam, co-principal investigator and endocrinologist at Mount Sinai Health System, said the results were the “clearest real-world picture yet” of risk stratification at scale. Dr Joji Tokita, also a co-principal investigator and a nephrologist at Mount Sinai, said the test had to show “durable kidney protection” and called the kidney function data “real change.” Investegate
The market’s focus is shifting to payment. Renalytix said Medicare will reimburse its kidneyintelX.dkd test at $950 for each reportable result. Over 15,000 patients have had the test. Renalytix in February guided for about $4.0 million in revenue for the year ending June 30, after reporting unaudited H1 FY26 revenue of $1.6 million.
The move snaps the stock reaction into focus. Renalytix set a $4.0 million full-year revenue target, which works out to around 4,200 reimbursed reportable results at $950, before any impact from mix, timing or life-sciences revenue. Back in March, Renalytix said life-sciences revenue came in at $0.5 million for the six months to Dec. 31. Testing-services revenue was $1.1 million.
The company is pushing scale through electronic medical record tie-ins. The March half-year report said fully integrated EHR systems are up to five from two. It added 58 new practice sites and started eight more integrations. When finished, those could give access to around 10,000 eligible patients.
Renalytix said in February that its new big hospital group integration included a proposed 1,000-patient pilot for 2026 and possible reach to over 40,000 chronic kidney disease patients. In the same update, the company said longer lead times and added complexity with bigger health-system EMR projects had slowed first-half revenue growth.
